Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Schlumberger M, et al. Among authors: wirth lj. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. N Engl J Med. 2015. PMID: 25671254 Free article. Clinical Trial.
Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Sherman SI, et al. Among authors: wirth lj. N Engl J Med. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853. N Engl J Med. 2008. PMID: 18596272 Free article. Clinical Trial.
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Schlumberger MJ, et al. Among authors: wirth lj. J Clin Oncol. 2009 Aug 10;27(23):3794-801. doi: 10.1200/JCO.2008.18.7815. Epub 2009 Jun 29. J Clin Oncol. 2009. PMID: 19564535 Clinical Trial.
Thyroid carcinoma.
Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ; National Comprehensive Cancer Network. Tuttle RM, et al. Among authors: wirth lj. J Natl Compr Canc Netw. 2010 Nov;8(11):1228-74. doi: 10.6004/jnccn.2010.0093. J Natl Compr Canc Netw. 2010. PMID: 21081783 No abstract available.
Cabozantinib in progressive medullary thyroid cancer.
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Elisei R, et al. Among authors: wirth lj. J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. J Clin Oncol. 2013. PMID: 24002501 Free PMC article. Clinical Trial.
Thyroid carcinoma, version 2.2014.
Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Tuttle RM, et al. Among authors: wirth lj. J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80; quiz 1680. doi: 10.6004/jnccn.2014.0169. J Natl Compr Canc Netw. 2014. PMID: 25505208
New frontiers and treatment paradigms for thyroid carcinoma.
Haddad R, Sherman SI, Shah JP, Wirth LJ. Haddad R, et al. Among authors: wirth lj. Clin Adv Hematol Oncol. 2014 Jul;12(7 Suppl 14):3-21; quiz 22. Clin Adv Hematol Oncol. 2014. PMID: 25768715 Review. No abstract available.
Lenvatinib in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ. Schlumberger M, et al. Among authors: wirth lj. N Engl J Med. 2015 May 7;372(19):1868. doi: 10.1056/NEJMc1503150. N Engl J Med. 2015. PMID: 25946295 No abstract available.
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Brose MS, et al. Among authors: wirth lj. Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23. Lancet Oncol. 2016. PMID: 27460442 Free PMC article. Clinical Trial.
171 results